Tell a Friend
captcha

 
x
Online Consultation - Imperial Healthcare - Institute Language  
Patients’ Experiences
Recent Advancements
Blog
Contact us
Center for Sight
 
 
 
 
The Eyelid Clinic
 
 
 
 
ALA Award:
Best Eye Care Clinic
of the Year 2015
 
 
 
 
Multifocal
Cataract Treatment
 
 
 
 
Botulinum toxin and Fillers
 
 
 
 
Removal of Eye Bags
 
 
 
 
Diabetic
Eye Treatment
 
 
 
 
Watery /
Dry Eye Treatment
 
 
 
 
Children’s Eye Care
 
 
 
 
Skin Laser
Rejuvenation
 
 
 
 
HD vision
with ICL Implants
 
 
 
 
Keratoconus Treatment
 
 
 
 

Intravitreal Injections of Anti VEGF (Lucentis, Avastin) & Triamcinolone

Intravitreal Injections of Anti VEGF (Lucentis, Avastin) & Triamcinolone Injections into the eye or surrounding tissues can be made for various reasons. Injections can be made into the vitreous of the eye (intravitreal), behind the eye (retrobulbar), below the conjunctiva (subconjunctival) or under tenon’s capsule (subtenons).

There are two types of Anti-VEGF Injections used here at Imperial Healthcare:

Avastin

Avastin is an antibody to vascular endothelial growth factor (VEGF), a protein responsible for angiogenesis (new blood vessel growth). Because of Avastin’s ability to bind to VEGF, the VEGF molecule is then unable to bind to its receptor which would lead to angiogenesis. Avastin is approved as an anti-tumor medication for use in specific cancer types. Although Avastin is not approved by the FDA for ocular use, it has proved to be highly efficacious for use in cases of retinal or choroidal neovascularization and macular edema. For ocular use, Avastin is administered via intravitreal injection into the central vitreous through the pars plana in a volume of 0.1mL. The drug can then travel to the back of the eye and through the retina where it binds excess VEGF and inhibits new blood vessel growth for as long as the drug is available.

Lucentis

Lucentis is a modified version of Avastin that has been optimized for ocular use. Like Avastin, Lucentis binds VEGF which stops VEGF from binding to its receptor and promoting angiognesis. Unlike Avastin which is a large antibody, Lucentis is an antibody fragment and is therefore much smaller and better able to penetrate the retina. Lucentis has specifically been designed for use in the eye to treat neovascular (wet) macular degeneration and is approved for this use by the FDA. Lucentis is administered by intravitreal injection into the middle of the vitreous through the pars plana in a volume of 0.05mL. The drug can then travel to the back of the eye and through the retina where it binds excess VEGF and inhibits new blood vessel growth for as long as the drug is available.

The other type of ocular injection used is the Anti-Inflammatory Injection. In particular, the Triamcinolone Acettonide is widely used here at the Imperial Healthcare:

Triamcinolone Acetonide

Corticosteroids are hormones that are produced naturally by the body. Triamcinolone acetonide is a synthetic corticosteroid. This class of compounds contains the most potent anti-inflammatory drugs available to us. They work by inhibiting certain reactions in cells which relate to the immune system and allergic responses that produce inflammation. Triamcinolone acetinde is a potent and fairly long lasting version of a corticosteroid. Because of it’s low water solubility, it remains in the eye for long periods of time, only releasing enough compound to be efficacious. Unfortunately, prolonged exposure to corticosteroids can cause high intraocular pressure and induce cataract formation. Triamcinolone is administered intravitreally and in subtenons injections.